@article{242d839db7b34761ac80fd3b25ed0939,
title = "Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy",
abstract = "The assessment of MPR was reproducible between observers. We confirmed that MPR is associated with OS and can serve as an independent prognostic factor in NSCLC patients undergoing neoadjuvant chemotherapy. Our data suggest that at least 3 slides should be read to accurately determine tumor response. Our results clearly demonstrate that MPR is a significant predictor of OS.",
keywords = "Endpoint, Lung cancer, MPR, Neoadjuvant chemotherapy, OS",
author = "Annikka Weissferdt and Apar Pataer and Vaporciyan, {Ara A.} and Correa, {Arlene M.} and Boris Sepesi and Moran, {Cesar A.} and Wistuba, {Ignacio I.} and Roth, {Jack A.} and Shewale, {Jitesh Baban} and Heymach, {John V.} and Neda Kalhor and Tina Cascone and Hofstetter, {Wayne L.} and Lee, {J. Jack} and Swisher, {Stephen G.}",
note = "Funding Information: This work was supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support Grant, CA 016672 (Lung Program), and by the Homer Flower Research Fund, the Charles Rogers Gene Therapy Fund, the Margaret Wiess Elkins Endowed Research Fund, the Flora and Stuart Mason Lung Cancer Research Fund, and the Phalan Thoracic Gene Therapy Fund. Publisher Copyright: {\textcopyright} 2019",
year = "2020",
month = jul,
doi = "10.1016/j.cllc.2019.11.003",
language = "English (US)",
volume = "21",
pages = "341--348",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "4",
}